Clinical trials: Cavernous Malformation, Cerebral, open to volunteers
Cavernous Malformation, Cerebral
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
Cerebral cavernous malformation (CCM) is a common vascular abnormality of the brain, affecting 0.1%-0.5% of people. It often causes recurrent brain hemorrhages, epilepsy, and neurological impairments, with surgery being the main…
- Trial name
- CCM-DS01 (NCT07026604)
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tiantan Hospital
CCM, Familial Cerebral Cavernous Malformation
Natural History of Familial Cerebral Cavernous Malformations: the CCM_Italia Cohort Study
Patients with symptomatic and asymptomatic familial cerebral cavernous malformation (fCCM) will be included. The goal of this observational study is to learn about the long-term evolution of this condition.
- Trial name
- CCM_Italia (NCT06983132)
- Testing
- Cerebral imaging (MRI) according to a dedicated protocol with central MRI reading, Determination of circulating biomarkers
- Where
- 6 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Cavernous Malformation, Cerebral, Cavernous Angioma
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate…
- Conditions
- Cavernous Malformation, Cerebral, Cavernous Angioma, Cavernous Hemangioma, Cavernous Hemangioma of Brain
- Trial name
- CRESS (NCT04076449)
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- yuanli Zhao
Hemangioma, Cavernous, Central Nervous System
Study on Treatment Decision-Making and Prognostic Follow-Up for Untreated Cerebral Cavernous Malformations
The goal of this observational study is to evaluate and predict the risk associated with cerebral cavernous malformations (CCMs) using advanced artificial intelligence and radiomics analysis technology.
- Trial name
- NCT06214767
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing Tiantan Hospital
Cerebral Cavernous Malformation
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
This Phase 1, dose-escalation, double-blind, multiple ascending dose (MAD) study was designed to assess the safety and tolerability of NRL-1049 compared to placebo in healthy adult participants and to determine the maximum…
- Trial name
- NCT07908134
- Testing
- NRL-1049
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Neurelis, Inc.
CADASIL, Cavernous Angioma
Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2
CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005.
- Conditions
- CADASIL, Cavernous Angioma, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Small Vessel Disease
- Trial name
- B-MRVC2 (NCT07650110)
- Testing
- Biocollection, Neurological evaluation and Biocollection
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris